ACYCLOVIR SODIUM FOR INJECTION POWDER FOR SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

ACYCLOVIR (ACYCLOVIR SODIUM)

Inapatikana kutoka:

ABBOTT LABORATORIES, LIMITED

ATC kanuni:

J05AB01

INN (Jina la Kimataifa):

ACYCLOVIR

Kipimo:

1G

Dawa fomu:

POWDER FOR SOLUTION

Tungo:

ACYCLOVIR (ACYCLOVIR SODIUM) 1G

Njia ya uendeshaji:

INTRAVENOUS

Vitengo katika mfuko:

5X20ML

Dawa ya aina:

Prescription

Eneo la matibabu:

NUCLEOSIDES AND NUCLEOTIDES

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0115506006; AHFS:

Idhini hali ya:

CANCELLED POST MARKET

Idhini ya tarehe:

2007-07-31

Tabia za bidhaa

PRODUCT MONOGRAPH
for
ACYCLOVIR SODIUM FOR INJECTION
(Acyclovir Sodium Sterile Powder)
ABBOTT STANDARD
500 mg Acyclovir/vial, 1 gram Acyclovir/vial
_Antiviral Agent_
Abbott Laboratories, Limited
DATE OF PREPARATION:
8401 Trans-Canada Highway
May 14, 1997
Saint-Laurent, Quebec, H4S 1Z1
DATE OF REVISION:
September 17, 2003
Control no. 083623
- 2 -
PRODUCT MONOGRAPH
NAME OF DRUG
ACYCLOVIR SODIUM FOR INJECTION
(Acyclovir Sodium Sterile Powder)
ABBOTT STANDARD
500 mg Acyclovir/vial and 1 gram Acyclovir/vial
THERAPEUTIC CLASSIFICATION
Antiviral Agent
ACTION AND CLINICAL PHARMACOLOGY
Acyclovir, a synthetic acyclic purine nucleoside analog, is a
substrate with a high degree of
specificity for herpes simplex and varicella-zoster specified
thymidine kinase. Acyclovir is a poor
substrate
for
host
cell-specified
thymidine
kinase.
Herpes
simplex
and
varicella-zoster
specified-thymidine kinase transform acyclovir to its monophosphate
which is then transformed by
a number of cellular enzymes to acyclovir diphosphate and acyclovir
triphosphate. Acyclovir
triphosphate is both an inhibitor of, and a substrate for, herpes
virus-specified DNA polymerase.
Although the cellular
"
-DNA polymerase in infected cells may also be inhibited by acyclovir
triphosphate, this occurs only at concentrations of acyclovir
triphosphate which are higher than
those which inhibit the herpes virus-specified DNA polymerase.
Acyclovir is selectively converted to its active form in herpes
virus-infected cells and is thus
preferentially taken up by these cells. Acyclovir has demonstrated a
very much lower toxic potential
_in vitro_ for normal uninfected cells because: 1) less is taken up;
2) less is converted to the active
form; 3) cellular
"
-DNA polymerase has a lower sensitivity to the action of the active
form of the
drug.
A combination of the thymidine kinase specificity, inhibition of DNA
polymerase and premature
termination of DNA synthesis results in inhibition of herpes virus
replication. No effect on latent
non-replicating virus has been demonstra